Uromodulin's role in multiple myeloma care
Part of Cancer clinical trials.
This study looks at a protein called uromodulin to see if it can help manage multiple myeloma, especially in patients with kidney problems caused by the disease. It may lead to better ways to track and treat kidney issues in myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been newly diagnosed with multiple myeloma (using updated 2024 guidelines)
- You may or may not have kidney problems from your myeloma
- Your kidney problems are not from other causes like diabetes, high blood pressure, or lupus
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
This study tests if a plant-based diet can help people with newly diagnosed multiple myeloma who are receiving a standard 4-cycle drug combination (DRVd). Researchers want to see if changing what you eat might improve treatment results.
This early-phase study tests whether taking a Vitamin D3 supplement can be safe and helpful for people with symptomatic multiple myeloma. It may help researchers understand how Vitamin D affects the disease and how patients tolerate treatment.
This trial tests a new treatment called UTAA17 that targets a protein on myeloma cells. It may be an option for people whose multiple myeloma has not responded to several prior treatments.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
Hear when a new Multiple Myloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.